The total return over the past 12 months is -25.56% vs. +16.94% for the S&P 500. So far it's up -35.01% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (25.56%) | +41.77% | +18.30% | N/A | N/A | N/A |
| Total Return CAGR | (25.56%) | +41.77% | +18.30% | N/A | N/A | N/A |
| Revenue CAGR | (88.87%) | (30.65%) | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
NewAmsterdam Pharma Company N.V. (NAMS)
| Year | Start price | End price | NAMS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $35.08 | $22.80 | (35.01%) | +14.51% | (49.52%) |
| 2025 | $25.70 | $35.08 | +36.50% | +17.72% | +18.78% |
| 2024 | $11.17 | $25.70 | +130.08% | +24.89% | +105.19% |
| 2023 | $10.90 | $11.17 | +2.48% | +26.19% | (23.71%) |
| 2022 | $9.75 | $10.90 | +11.79% | (18.17%) | +29.96% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
